IngredientsBlessed thistle (Cnicus benedictus L., synonym Centaurea benedicta L.) is an annual plant belonging to the family Asteraceae. Its common names include Carduus benedictus, Holy thistle, Spotted thistle, and St. Benedict's thistle. The Latin epithet benedictus was derived from the plant's reputation for immense healing properties, implying sacred or blessed virtues. In various languages it is also known by distinct names: in Arabic as kanterion mubark or shok marimi; in Chinese as cang ye hua; in French as chardon bénit; and in German as Benediktenkraut or Bitterdistel.
Blessed thistle originated in the Mediterranean region. It has since been introduced in most parts of Europe, Asia, South Africa, and Central America. The plant is an annual growing to 0.6 m (approximately 2 feet) in height. The upper leaves are sessile and the lower ones are petioled. The flower heads are yellow and surrounded by spine-tipped bracts. The whole plant — leaves, stalks, and flower heads — is covered with a thin down.
The European Medicines Agency's (EMA) Committee on Herbal Medicinal Products (HMPC) has issued scientific conclusions regarding the medicinal uses of the above-ground parts of Cnicus benedictus, with these conclusions taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing the plant. The U.S. Food and Drug Administration recognizes blessed thistle as generally recognized as safe (GRAS) as a flavoring in alcoholic beverages (e.g., Benedictine).
The plant's dried leaves, stems, and flowers have been used medicinally. Medicinal products with St. Benedict's thistle contain the comminuted (reduced into tiny pieces), the powdered, and liquid extract or tincture of the dried above-ground part of the plant. Liquid extracts and tinctures are obtained by putting the plant material in a solvent (like ethanol) to dissolve compounds. Herbal medicines containing the plant's above-ground part preparations are usually available as herbal tea and in liquid or solid dosage forms to be taken by mouth. Blessed thistle herb is also used as an additive in bitter schnapps and herb liqueurs.
Blessed thistle, historically known as Carduus benedictus, has been used since the Middle Ages primarily as a remedy for digestive issues and to stimulate appetite. Monks and early herbalists valued it for treating fevers, infections, and wounds. By the early sixteenth century, it had securely gained footing in European folk medicine and was cultivated widely in monastery gardens. Its specific name is in honor of St. Benedict, the founder of a holy order of monks. The plant was widely cultivated during the Middle Ages in Europe and was used in many herbal formulations of the period. It was thought to be useful against the bubonic plague; however, its main uses were for treatment of digestive complaints, gout, fever, and headache.
It was a component of many herbal remedies used to combat the plague. The herb was cultivated in monastery gardens as a cure for smallpox. Blessed thistle was also recommended as an emmenagogue and galactogogue, and for the treatment of intestinal worms.
It was also used to support women's reproductive health, especially for enhancing milk production in nursing mothers. Blessed thistle's use as a galactagogue dates back to the Middle Ages. Traditionally, it was consumed as a tea to support lactation, especially in Europe. It was also used to treat a variety of ailments, including indigestion, colds, and fever. The herb was often combined with other lactogenic herbs to enhance its effectiveness in supporting milk production.
The famous poet Shakespeare mentioned blessed thistle in his play Much Ado About Nothing (written in 1598–1599 CE). Spiritually, it was associated with purification and was therefore used in purification baths. It was also believed that wearing a bit of it would protect one from evil. Furthermore, it was associated with the planet Mars, the zodiac of Aries, and the element fire.
In European folk herbalism, blessed thistle was mainly used as a bitter tonic to treat dyspepsia, flatulence, and indigestion. Some herbalists also recommended it as an astringent (to treat diarrhea or hemorrhage), as a vulnerary, galactogogue, and remedy for dysmenorrhea. In folk medicine, an infusion made from C. benedictus is considered a general tonic, expectorant, and beneficial for the digestive system.
C. benedictus contains a variety of chemical compounds, such as glycosides, triterpenoids, lignans, flavonoids, phenolic acids, steroid compounds, volatile oils (0.3%), tannins (8%), and mineral components. The plant is rich in a diverse array of bioactive molecules, with the sesquiterpene lactone cnicin recognized as the signature compound.
The most prominent constituent of blessed thistle is the bitter sesquiterpene lactone ester cnicin. Dried leaves of Cnicus benedictus L. contain up to 2.5% of cnicin, while commercial herbs contain between 0.2–0.7%. Shoots and flowering heads are almost free from this bitter substance. Storage of dried plant material leads to high losses due to the instability of cnicin. Additional sesquiterpene lactones identified include salonitenolide, artemisiifolin, and absinthin.
Lignans present in the plant include trachelogenin, nortracheloside, and arctigenin. Lignans such as trachelogenin, as well as cnicin, contribute to the bitter characteristics of blessed thistle.
Triterpenoids identified include α-amyrenone, α-amyrin acetate, α-amyrine, and multiflorenol acetate.
Flavonoids include apigenin-7-O-glucoside, luteolin, and astragalin. The plant also contains phenolic compounds, saponins, alkaloids, starch, glycosides, triterpenes, and coumarins.
Tannin contents reach up to 8%. Essential and volatile oils (0.3%) include n-nonane, n-undecane, n-tridecane, a polyyne (dodeca-l,11-dien-3,5,7,9-tetrayne), p-cymene, fenchone, citral, and cinnamaldehyde.
The leaves and plant parts contain a high mineral content, primarily potassium, manganese, magnesium, and calcium. The seed oil of Cnicus benedictus is a good source of linoleic acid (greater than 70% of total fatty acids) and α-tocopherol (greater than 90% of total tocopherols).
Cnicin has been shown to stimulate secretion of gastric juices and saliva, and potentially bile, based on its identity as a bitter principle. A primary component of C. benedictus, acting as an amaroid (bitter principle), has been used to treat anorexia because it promotes the release of saliva and gastric fluids.
The anti-inflammatory effects of C. benedictus have been shown to involve suppression of nuclear factor κB (NF-κB) and inducible nitric oxide synthase (iNOS), and a decrease in reactive oxygen species (ROS). Cnicin interacts with cyclooxygenase-1 and nitric oxide synthase through conventional hydrogen bonds, indicating inhibition of these enzymes. Cnicin shows anti-inflammatory activity in the rat paw edema screen which is nearly equivalent to that of indomethacin.
Pharmacokinetic studies show that following oral ingestion of blessed thistle by rats, the lignans arctiin and tracheloside are metabolized to their genins, arctigenin and trachelogenin. Studies on rats indicate that these lignans appear to exert inhibitory effects on cyclic AMP, phosphodiesterase, and histamine release in mast cells. Platelet activating factor (PAF) antagonist activities have also been observed, as well as antagonist action against calcium ions.
The sesquiterpene lactone cnicin has a structure allowing it to form covalent bonds with proteins. This is due to the α-methylene-γ-lactone structures of bitter terpenoid lactones, which are known to have antibacterial properties. Cnicin's antimicrobial action is mediated through the disruption of microbial cell membranes, inhibition of essential enzymes, and interference with microbial biofilm formation.
Blessed thistle has been traditionally used to stimulate secretion of gastric juices and saliva, to increase appetite and facilitate digestion, and to stimulate the flow of bile. Medicines using the above-ground parts of Cnicus benedictus for symptomatic relief of dyspepsia and mild spasmodic disorders of the gastrointestinal tract and for the temporary loss of appetite are classified in the EU as being based on "traditional use." No clinical studies have been found on the effects of Cnicus benedictus herba on any disease. The existing data do not meet the criteria for "well established medicinal use" in accordance with EU Directive 2001/83/EC. The plausibility of efficacy is based on long-standing use and experience.
Evidence strength: Anti-inflammatory, antimicrobial, and cytotoxic activities have been reported and are thought to be due to the chemical constituent cnicin; however, there are no clinical trials to support these potential uses. The digestive indication rests on traditional use and pre-clinical data only, with no controlled human trials identified by any major review.
Blessed thistle is a purported galactogogue and is included in some proprietary mixtures promoted to increase milk supply; however, no scientifically valid clinical trials support this use. A systematic review of herbal and pharmaceutical galactagogues found that, although blessed thistle was identified as among the most commonly used herbs to induce or augment lactation, no peer-reviewed publications on its use as a herbal preparation were identified that met inclusion criteria.
Blessed thistle was identified as one of the four most common herbs used by certified or licensed midwives for increasing lactation based on state-wide surveys in California, Texas, and North Carolina. A review published in The Journal of Alternative and Complementary Medicine highlighted the potential of herbal galactagogues, including blessed thistle, in enhancing milk production but emphasized the need for more rigorous clinical trials to validate these findings.
Evidence strength: While blessed thistle is widely recommended as a galactagogue, the scientific evidence supporting its use is limited. Most of the available research focuses on its use in combination with other herbs like fenugreek. No standalone, adequately powered, blinded, randomized controlled trial has been identified in the peer-reviewed literature.
In vitro studies examining the effects of cnicin and the essential oil of blessed thistle against Bacillus subtilis, Brucella species, Escherichia coli, Proteus species, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus faecalis show that these constituents possess antibacterial activity against these strains, suggesting a broad spectrum of antimicrobial activity.
Evidence strength: Most of the antimicrobial studies were preliminary and only tested relatively high concentrations of the extracts. Additionally, most studies screened a limited number of pathogens. All antimicrobial evidence is from in vitro or animal models; no human trials exist.
Extracts of C. benedictus and its compound cnicin reduce chemically induced inflammation in mice, suggesting new possibilities for therapeutic development. One study evaluated the topical anti-inflammatory potential of an extract and cnicin from C. benedicta leaves in a mouse model. Activity was assessed using the ear edema method with croton oil, phenol, capsaicin, and histamine as phlogistic agents. Markers of edema and inflammation including myeloperoxidase, TNF-α, IL-6, and nitric oxide were assessed.
Evidence strength: All anti-inflammatory evidence derives from cell-based and animal studies. No human clinical trials have been conducted.
Studies investigating the antineoplastic and cytotoxic effects of constituents in blessed thistle have been done, examining effects against tumor cell lines including leukemia (HL-60), hepatomas, and sarcomas. These studies indicate that the constituents cnicin and arctigenin exhibit antitumor activity via inhibition of cellular DNA, RNA, or protein synthesis. In vitro studies have demonstrated that cnicin, arctigenin, and arctiin inhibit the proliferation of DU-145 prostate cancer cells, MCF-7 (breast cancer cells), and MCF-12A (non-malignant breast cells). In contrast, a crude extract from C. benedictus does not exhibit such activity.
In vitro anticancer properties of cnicin were demonstrated against four human solid tumor cell lines: breast ductal carcinoma (BT-549), ovary carcinoma (SK-OV-3), oral epidermal carcinoma (KB), and malignant melanoma (SK-MEL) cells. Mild cytotoxicity was observed for cnicin toward LLC-PK11 cells (IC50 = 23 µM), but no significant effects were noted against Vero cells. Antitumor effects were observed for cnicin toward SK-MEL and BT-549 cancer cell lines.
Interestingly, pure cnicin has good anticancer activity, while the crude extracts lack cytotoxic properties. There have been studies investigating several lignans in Cnicus benedictus as possible anti-HIV and anti-cancer agents, but so far the evidence remains unclear.
Evidence strength: A limited number of research studies have determined the toxicity profile of C. benedicta in order to evaluate its safety for human use. Substantially more detailed studies are required to rigorously investigate the therapeutic properties and phytochemistry of C. benedicta, which may ultimately lead to the development of new plant-based therapeutic medicines. All anticancer evidence is preclinical (in vitro and animal); no human trials have been reported.
Cnicin, the sesquiterpene lactone found in blessed thistle, has shown antiparasitic activities, though it has poor water solubility, which may limit its antiparasitic activities in practice. Research has investigated cnicin and its cyclodextrin inclusion complexes for activity against Schistosoma mansoni, primarily at the in vitro and animal model level. No human studies exist in this area.
A number of phenolics and flavonoids in C. benedictus extract have demonstrated significant ferric-reducing antioxidant power (FRAP), 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activity, as well as xanthine oxidase inhibitor characteristics. These findings are from in vitro assays and have not been translated into clinical outcomes.
Doses of 4 to 6 g daily have been traditionally used. More specifically, a daily dosage of 4 to 6 g of the dried herb has been described in traditional references. For use as an aromatic bitter, one cup of infusion is taken half an hour before meals, with one cup of tea taken three times a day. For tincture preparations, 1–2 mL of the tincture is taken three times a day.
No clinical studies exist to provide evidence-based dosing recommendations for blessed thistle. Herbal medicines containing holy thistle above-ground part preparations are usually available as herbal tea to be drunk, and in liquid or solid dosage forms to be taken by mouth. The EMA monograph specifies oral use before meals, but the full dosage schedule is defined within the official monograph documentation.
In doses greater than 5 grams per cup of tea, blessed thistle might cause stomach upset and vomiting. Post-market surveillance data indicated that blessed thistle, when taken at high doses (greater than 5 g per cup of tea), may cause stomach irritation and vomiting.
In proprietary combination preparations such as "Mother's Milk Tea," blessed thistle is included as one ingredient at 35 mg, combined with other herbs. Blessed thistle is a common ingredient in combination formulas for gastric health.
Blessed thistle overdose may cause gastrointestinal irritation, nausea, and vomiting, which should resolve with discontinuation of blessed thistle and adequate fluid intake. Eight percent of mothers taking blessed thistle reported experiencing adverse reactions, most commonly nausea, stomach cramps, dry mouth, and fatigue.
Because blessed thistle is a member of the ragweed family, allergy is a concern, and high doses reportedly cause stomach cramps, nausea, and vomiting. Blessed thistle might cause an allergic reaction in people who are sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many others. Allergy and hypersensitivity to blessed thistle have been reported. Caution is recommended in people sensitive to other asteraceous plants.
Elevated liver enzymes occurred in a woman taking Mother's Milk Tea, which contains blessed thistle and other ingredients. This is a case report involving a combination product, and causation by blessed thistle specifically could not be definitively established.
Blessed thistle is contraindicated in patients with gastric ulcers or other inflammatory bowel conditions, such as Crohn disease. Individuals with intestinal problems, such as infections, Crohn's disease, and other inflammatory conditions should not take blessed thistle, as it might irritate the stomach and intestines.
Blessed thistle has been traditionally used as an emmenagogue and should not be used in pregnancy. As there is no information on reproductive and developmental toxicity, the use during pregnancy and lactation cannot be recommended. Information regarding safety and efficacy during lactation is lacking.
Antacids are used to decrease stomach acid. Blessed thistle can increase stomach acid, and therefore taking blessed thistle might decrease the effects of antacids. H2-blockers are used to decrease stomach acid. Blessed thistle can increase stomach acid, and taking blessed thistle might decrease the effects of H2-blockers. Common H2-blockers include cimetidine (Tagamet), ranitidine (Zantac), and famotidine (Pepcid). Similar pharmacodynamic antagonism has been theorized with proton pump inhibitors.
Specific data on pharmacokinetics and interactions with the whole herb are not available. Non-clinical information on the safety of Cnicus benedictus herba is scarce.
The approximate acute toxicity (ALD50) for mice administered cnicin orally is 1.6–3.2 mmol cnicin/kg body weight. Intraperitoneal application of cnicin results in strong irritation of tissue. These figures pertain to the isolated compound at experimental doses and are not directly applicable to typical human supplementation.
The overall evidentiary base for blessed thistle remains limited. No clinical studies have been found on the effects of Cnicus benedictus herba on any disease in humans. Despite a limited amount of high-quality scientific data, the bitter components in C. benedictus provide a plausible mechanistic rationale for its traditional digestive applications. The herb's status across all major regulatory and evidence-based frameworks is that of a traditional herbal medicinal product whose plausibility rests on historical use and mechanistic pre-clinical data, not on the results of controlled human trials. Promising areas — including antimicrobial, anti-inflammatory, and anticancer activities — have only been explored at the in vitro and animal levels, and substantially more research is required before clinical claims can be made.
Health conditions that Blessed thistle may help support.
Blessed thistle is Commission E-approved for nonspecific dyspepsia, underpinning its traditional role in relieving abdominal discomfort including bloating, gas, cramping, and indigestion. Cnicin stimulates gastric secretions and bile flow, addressing symptoms arising from digestive insufficiency. Evidence is traditional and pharmacological rather than from human clinical trials.
Blessed thistle contains flavonoids, sesquiterpene lactones, and polyphenols that exhibit antioxidant activity in vitro, including inhibition of acetylcholinesterase and free-radical scavenging. In vitro antioxidant activity is documented in peer-reviewed literature. No human studies have evaluated antioxidant effects in vivo.
Blessed thistle has been approved by Germany's Commission E for loss of appetite, based on its well-documented traditional use as a bitter tonic. The sesquiterpene lactone cnicin stimulates salivary and gastric secretions through a reflex mechanism common to bitter herbs. No controlled human clinical trials have confirmed this effect specifically for blessed thistle.
Blessed thistle was historically used as a remedy for arthritis, gout, and rheumatism in European folk medicine. This use is recorded in traditional herbal texts and pharmacopoeias. There is no pharmacological or clinical trial evidence specifically investigating blessed thistle for arthritis.
Blessed thistle (Cnicus benedictus) is a widely used traditional galactagogue commonly recommended alongside fenugreek by lactation specialists. The NIH LactMed database confirms it is included in proprietary lactation products but states no scientifically valid clinical trials support this use. Traditional use is documented in multiple cultures for milk production support. An Australian survey found it rated as slightly to moderately effective by nursing mothers who used it.
Cnicin, the primary active constituent of blessed thistle, has demonstrated anti-inflammatory activity in vitro and in animal models, including reduction of markers such as TNF-α, IL-6, and MPO. Pharmacological screening in rat paw edema tests showed efficacy comparable to indomethacin. No human clinical trials have confirmed anti-inflammatory effects in chronic inflammatory conditions.
Blessed thistle has been used traditionally as an expectorant and antimicrobial agent to address colds, respiratory infections, and flu-like illness. Its essential oil has demonstrated in vitro antibacterial activity against organisms such as Staphylococcus aureus. In vitro antiviral activity of aqueous extracts has also been reported in tissue culture. No human trials support these uses.
Blessed thistle contains tannins that are traditionally credited with astringent action on the gastrointestinal mucosa, potentially reducing diarrheal symptoms. A mild infusion is described in traditional sources as astringent and soothing to the gut. There are no clinical trials specifically evaluating blessed thistle for diarrhea.
Blessed thistle has been used since the Middle Ages as a diaphoretic (sweat-inducing) herb for the management of fever. Warm infusions were taken to induce perspiration and reduce body temperature during febrile states. This use is well documented in historical herbals including Turner's Herbal (1568), with no supporting clinical trials.
Blessed thistle has a well-established traditional use for gallbladder complaints, functioning as a cholagogue to stimulate bile flow. Historical herbals, the British Herbal Compendium, and the German and British pharmacopoeias recognize this application. No clinical trials have been conducted specifically for gallbladder disease.
Blessed thistle has a long traditional use as a hepatic tonic and liver stimulant, with documented use for jaundice, liver sluggishness, and liver complaints. The bitter constituents are thought to stimulate bile production and liver activity. Animal data suggest some hepatoprotective effects, but no human clinical trials confirm liver detoxification benefits.
Blessed thistle has been used traditionally as an emmenagogue and for relief of menstrual pain and cramps. Historical herbals and folk medicine consistently document this use, including for dysmenorrhea and amenorrhea. There is no clinical trial evidence supporting efficacy for menstrual pain.
Blessed thistle is traditionally classified as a diuretic, increasing urine output and thereby reducing fluid retention. This property is documented in historical herbals and pharmacopoeia monographs. The herb is also noted as being rich in potassium and sodium, electrolytes relevant to fluid balance. No clinical trials support diuretic efficacy in humans.
Blessed thistle has a documented traditional use as a topical antiseptic and wound-healing agent, applied as a poultice or decoction to boils, skin ulcers, and wounds. Its antimicrobial and anti-inflammatory properties from cnicin and the essential oil underlie this use. No clinical trials in wound healing have been conducted.
Body systems that Blessed thistle may help support.
Go back